Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech stock that is racking up profit thanks to a fast-growing cancer drug.
It's anyone's guess whether these three biotech stocks will continue their winning ways in the months and years to come, but I've prepared a slideshow below that highlights what you need to know about PTC Therapeutics (NASDAQ:PTCT), Tesaro (NASDAQ:TSRO), and Pharmacyclics (UNKNOWN:PCYC.DL) and why each of them have recently surged by 25% or more.
Todd Campbell is long Pharmacyclics. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.